logo-loader
viewDestiny Pharma plc

Destiny Pharma awaits key inflection point mid--2020 in its antimicrobial Phase 2b clinical trial

Destiny Pharma (LON:DEST) CEO Neil Clark spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The UK-based, clinical phase biotechnology company is focused on preventing post-surgical infection in a Phase 2b clinical trial with its lead asset. According to its website, Destiny is building a portfolio of antimicrobial drug products that to combat the threat of antimicrobial resistance (AMR).

Quick facts: Destiny Pharma plc

Price: 36.5 GBX

AIM:DEST
Market: AIM
Market Cap: £16.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Red Rock's Andrew Bell outlines next steps for exploration at its Luanshimba...

Red Rock Resources PLC's (LON:RRR) Andrew Bell tells Proactive London what's in store as far as phase two of exploration at its Luanshimba licence in the copper belt in the Democratic Republic of Congo, near the Zambian border. Red Rock will do pitting and trenching on the licence and then...

15 minutes ago

2 min read